Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration
暂无分享,去创建一个
[1] Michael Khalil,et al. Neurofilaments as biomarkers in multiple sclerosis , 2012, Multiple sclerosis.
[2] K. Blennow,et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.
[3] K. Haglid,et al. A Rapid HPLC Method to Separate the Triplet Proteins of Neurofilament , 1987, Journal of neurochemistry.
[4] Nick C Fox,et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[5] L. Grinberg,et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration , 2014, Annals of neurology.
[6] N. Norgren,et al. Monoclonal antibodies selective for low molecular weight neurofilaments. , 2002, Hybridoma and hybridomics.
[7] M. Staufenbiel,et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.
[8] N. Norgren,et al. Elevated neurofilament levels in neurological diseases , 2003, Brain Research.
[9] K. Haglid,et al. Polyclonal Antisera to the Individual Neurofilament Triplet Protdins: A Characterization Using ELISA and Immunoblotting , 1989, Journal of neurochemistry.
[10] T. Olsson,et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab , 2011, Annals of neurology.
[11] C. Wikkelsø,et al. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.